PE20220942A1 - COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO - Google Patents

COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO

Info

Publication number
PE20220942A1
PE20220942A1 PE2022000005A PE2022000005A PE20220942A1 PE 20220942 A1 PE20220942 A1 PE 20220942A1 PE 2022000005 A PE2022000005 A PE 2022000005A PE 2022000005 A PE2022000005 A PE 2022000005A PE 20220942 A1 PE20220942 A1 PE 20220942A1
Authority
PE
Peru
Prior art keywords
present
amount
composition
preparation
inhibitor
Prior art date
Application number
PE2022000005A
Other languages
English (en)
Spanish (es)
Inventor
Fude Huang
Feng Wang
Shu Yang
Changping Jiao
Xiaojun Zhou
Original Assignee
Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuo Beta Pharmaceutical Tech Shanghai Co Ltd filed Critical Nuo Beta Pharmaceutical Tech Shanghai Co Ltd
Publication of PE20220942A1 publication Critical patent/PE20220942A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PE2022000005A 2019-07-05 2020-07-06 COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO PE20220942A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019094831 2019-07-05
PCT/CN2020/100377 WO2021004422A1 (zh) 2019-07-05 2020-07-06 小分子PI4KIIIα抑制剂组合物、其制备方法及用途

Publications (1)

Publication Number Publication Date
PE20220942A1 true PE20220942A1 (es) 2022-05-31

Family

ID=74115038

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000005A PE20220942A1 (es) 2019-07-05 2020-07-06 COMPOSICION DE UN INHIBIDOR DE PI4KIIIalfa DE MOLECULA PEQUENA, METODO DE PREPARACION Y APLICACION DEL MISMO

Country Status (15)

Country Link
US (1) US20230115711A1 (cg-RX-API-DMAC7.html)
EP (1) EP3995134A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022538505A (cg-RX-API-DMAC7.html)
KR (1) KR20220071175A (cg-RX-API-DMAC7.html)
CN (2) CN114555056B (cg-RX-API-DMAC7.html)
AU (1) AU2020309681A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022000155A2 (cg-RX-API-DMAC7.html)
CA (1) CA3149104A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022001218A2 (cg-RX-API-DMAC7.html)
IL (1) IL289586A (cg-RX-API-DMAC7.html)
MX (1) MX2022000287A (cg-RX-API-DMAC7.html)
PE (1) PE20220942A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022550254A1 (cg-RX-API-DMAC7.html)
TW (1) TW202126294A (cg-RX-API-DMAC7.html)
WO (1) WO2021004422A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114685566A (zh) * 2020-12-31 2022-07-01 江苏挪贝肽医药科技有限公司 氧化苯砷晶型i、晶型ii和晶型iii及其制备方法
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.
CN116478954B (zh) * 2023-02-14 2025-06-10 中国农业大学 水稻基因OsPI4K及其在水稻抗稻瘟病中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002365110A1 (en) * 2001-07-10 2003-07-15 Massachusetts Institute Of Technology Small molecule microarrays
EP2319926B1 (en) * 2007-07-05 2016-08-31 Arrowhead Research Corporation DSRNA for treating viral infection
WO2016172952A1 (zh) * 2015-04-30 2016-11-03 江苏挪贝肽医药科技有限公司 PI4KIIIα蛋白及相关的膜蛋白复合体在治疗阿尔茨海默病中的应用
WO2019200043A1 (en) * 2018-04-11 2019-10-17 New Mexico Tech University Research Park Coporation Lipid prodrugs for use in drug delivery
EP4130014A4 (en) * 2020-03-31 2024-05-15 Nuo-Beta Pharmaceutical Technology (Shanghai) Co., Ltd. Deuterated oxophenylarsine compound and use thereof
MX2024004055A (es) * 2021-09-30 2024-06-19 Nuo Beta Pharmaceutical Tech Shanghai Co Ltd Compuesto de oxido de fenilarsina halogenado y aplicacion del mismo.

Also Published As

Publication number Publication date
KR20220071175A (ko) 2022-05-31
CN118105372A (zh) 2024-05-31
EP3995134A4 (en) 2023-07-12
WO2021004422A1 (zh) 2021-01-14
JP2022538505A (ja) 2022-09-02
IL289586A (en) 2022-03-01
EP3995134A1 (en) 2022-05-11
CA3149104A1 (en) 2021-01-14
CN114555056B (zh) 2024-01-05
TW202126294A (zh) 2021-07-16
AU2020309681A1 (en) 2022-02-24
BR112022000155A2 (pt) 2022-04-12
US20230115711A1 (en) 2023-04-13
CO2022001218A2 (es) 2022-05-20
PH12022550254A1 (en) 2023-06-26
MX2022000287A (es) 2022-06-16
CN114555056A (zh) 2022-05-27

Similar Documents

Publication Publication Date Title
PY2085961A (es) Formulaciones de cannabinoides orales
AR112536A1 (es) Métodos para reducir la formación de partículas y composiciones elaboradas a través de los mismos
MX2022002548A (es) Composiciones medicinales estables de cannabidiol.
BR112023021160A2 (pt) Lipídeos ionizáveis e composições para liberação em ácido nucleico
MA40111B1 (fr) Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1
AR108074A1 (es) Composiciones de hormona esteroide en aceites de cadena media
CL2022002566A1 (es) Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572)
PE20050138A1 (es) Aceites de pescado con un perfil alterado de acidos grasos, un metodo para producir esos aceites y uso de ellos
BR112013020167A2 (pt) melhoradores de permeação para formulações tópicas
BRPI0916936B8 (pt) composições farmacêuticas, uso de clevidipina e método de reduzir impurezas.
PA8622001A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
MX2021015311A (es) Formulas parenterales de lisofosfatidilcolina tales como lpc-dha, lpc-epa y sus usos en terapia.
BR112015028696A2 (pt) composições de óleo estruturadas
MX2021014371A (es) Composiciones que comprenden acidos grasos cetilados y uso de las mismas en el tratamiento de la artritis y de afecciones inflamatorias de las articulaciones.
UY33404A (es) Composiciones farmacéuticas topicas
MX2021014297A (es) Procedimiento para preparar una composicion que comprende acidos grasos cetilados.
EP3116313B1 (en) Optic neuropathy treatment and reduction of steroid-induced oxidative stress with stabilized polyunsaturated substances
ECSP22047989A (es) Formulaciones que comprenden un mineral y/o una vitamina y un polisac?rido, composiciones de las mismas y uso de las mismas en la suplementaci?n de dicho mineral y/o vitamina
PE20211198A1 (es) Metodos y formulaciones para tratar nauseas y vomitos inducidos por quimioterapia
CA2739376A1 (en) Stabilized composition for treating psoriasis
ES3063367T3 (en) Composition having improved voluntary acceptance
MX2022006502A (es) Composiciones farmaceuticas.
CN101888837B (zh) 提高辅酶q10生物利用度的辅酶q10和大蒜油的组合物
BR112021022388A2 (pt) Uso de micelas de proteína de soro de leite para controlar a resposta de glicose pós-prandial
AR128535A1 (es) Composición para el cuidado del cabello